Evidence map›Paper›PMID 42749982›Full record

ArticleMolecular biotechnology2026

PCR-LbCas12a Assay for Genotyping of HPV 16 and 18.

ChonIl Paek, Jin Zhou, HuiYon Sin

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

ChonIl PaekFaculty of Life Science, KIM IL SUNG University, Pyongyang, Democratic People's Republic of Korea. ci.paek0112@ryongnamsan.edu.kp.ORCID http://orcid.org/0009-0009-3676-839X
Jin ZhouState Key Laboratory of Virology, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, China.
HuiYon SinFaculty of Life Science, KIM IL SUNG University, Pyongyang, Democratic People's Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR/Cas12a systems have been widely used in nucleic acid detection, because of their high specificity and trans-cleavage activity. We combined the specificity of CRISPR/Cas12a system with the sensitivity of PCR, to develop a new HPV detection assay with high specificity and sensitivity, called PCR-LbCas12a assay. Here, we pre-amplified almost all high-risk HPV genotypes with consensus primer (MY09/11) and added to new tubes containing HPV 16 or 18 CRISPR/Cas12a system for HPV genotyping. The LOD of PCR-LbCas12a for HPV16 or HPV18 DNA was 100 copies and 10 copies per reaction, respectively. In mixed samples of HPV 16 and HPV 18 DNA, PCR-LbCas12a assay could detect HPV16 DNA from samples containing 10

Indexed as

CRISPR-Cas12aHPV 16 and 18 detectionsHPV genotypingHuman papillomavirus (HPV)PCR-LbCas12a assay

Identifiers

PMID42749982

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.